<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00386581</url>
  </required_header>
  <id_info>
    <org_study_id>9081</org_study_id>
    <secondary_id>B4Z-MW-LYCZ</secondary_id>
    <nct_id>NCT00386581</nct_id>
  </id_info>
  <brief_title>Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder</brief_title>
  <official_title>Phase III Multicenter, Randomized, Double-Blind Placebo-Controlled Outpatient Study of Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <brief_summary>
    <textblock>
      The study is designed to investigate the acute treatment efficacy, safety, and tolerability&#xD;
      of atomoxetine on a once-daily dosing strategy (in the morning). It incorporates a 6-week&#xD;
      acute treatment period and a 2-week discontinuation phase. The assessments in this study&#xD;
      include a standard assessment of ADHD symptomatology using a Diagnostic and Statistical&#xD;
      Manual of Mental Disorders, Fourth Editionâ„¢, investigator-administered rating scale.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of atomoxetine administered as a single-daily dose with placebo in Russian children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare improvement in symptoms associated with ADHD in children and adolescents achieved by once-daily dosing of atomoxetine or placebo, defined by a more than 25% reduction in the ADHDRS-IV-Parent:Inv total score and by mean reductions in Conners</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of once-daily dosing of atomoxetine in Russian children and adolescents</measure>
  </secondary_outcome>
  <enrollment type="Actual">105</enrollment>
  <condition>Attention Deficit Disorder With Hyperactivity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atomoxetine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Subjects must have ADHD that meets the DSM-IV criteria&#xD;
&#xD;
          -  Aged 6 to 16 years.&#xD;
&#xD;
          -  Subjects must not have taken any medication used to treat ADHD.&#xD;
&#xD;
          -  Laboratory results must show no significant abnormalities&#xD;
&#xD;
          -  Baseline ECG results must not show an abnormality&#xD;
&#xD;
          -  Subjects must be able to swallow capsules.&#xD;
&#xD;
          -  Subjects must be of normal intelligence.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Weigh less than 20 kg or more than 60 kg at study entry.&#xD;
&#xD;
          -  Subjects who, after an adequate trial with methylphenidate or amphetamine experience&#xD;
             some benefit in ADHD signs and symptoms are excluded from participating.&#xD;
&#xD;
          -  Have a history of Bipolar I or II disorder, psychosis, or PDD.&#xD;
&#xD;
          -  Meet DSM-IV criteria for an anxiety disorder.&#xD;
&#xD;
          -  Have a history of any seizure disorder.&#xD;
&#xD;
          -  Patients at serious suicidal risk.&#xD;
&#xD;
          -  Patients with narrow angle glaucoma&#xD;
&#xD;
          -  Subjects who have a history of severe allergies .&#xD;
&#xD;
          -  Have a history of alcohol or drug abuse within the past 3 months&#xD;
&#xD;
          -  Screen positive for drugs of abuse not prescribed by a physician.&#xD;
&#xD;
          -  Have cardiovascular disease and an increased heart rate and blood pressure.&#xD;
&#xD;
          -  Have a medical condition that would increase sympathetic nervous system activity&#xD;
             markedly or who are taking a medication on a daily basis.&#xD;
&#xD;
          -  Have severe gastrointestinal narrowing&#xD;
&#xD;
          -  Are during the study time likely to need psychotropic medications.&#xD;
&#xD;
          -  Are likely to begin a structured psychotherapy aimed at ADHD symptoms.&#xD;
&#xD;
          -  Have used a monoamine oxidase inhibitor (MAOI) during the 2 weeks&#xD;
&#xD;
          -  Female subjects who are pregnant or who are breast-feeding.&#xD;
&#xD;
          -  Are investigative site personnel directly affiliated with the study, or are immediate&#xD;
             family of investigator site personnel directly affiliated with the study.&#xD;
&#xD;
          -  Are, in the opinion of the investigator, unsuitable in any other way to participate in&#xD;
             this study.&#xD;
&#xD;
          -  Are employed by Lilly.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>June 2007</verification_date>
  <study_first_submitted>October 6, 2006</study_first_submitted>
  <study_first_submitted_qc>October 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2006</study_first_posted>
  <last_update_submitted>June 11, 2007</last_update_submitted>
  <last_update_submitted_qc>June 11, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

